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Bcl-3 is a distinctive member of the IB family of NF-B inhibitors because it can function to coactivate
transcription. A potential involvement of Bcl-3 in oncogenesis is highlighted by the fact that it was cloned due
to its location at a breakpoint junction in some cases of human B-cell chronic lymphocytic leukemia and that
it is highly expressed in human breast tumor tissue. To analyze the effects of Bcl-3 dysregulation in breast
epithelial cells, we created stable immortalized human breast epithelial cell lines either expressing Bcl-3 or
carrying the corresponding vector control plasmid. Analysis of the Bcl-3-expressing cells suggests that these
cells have a shortened G1 phase of the cell cycle as well as a significant increase in hyperphosphorylation of
the retinoblastoma protein. Additionally, the cyclin D1 gene was found to be highly expressed in these cells.
Upon further analysis, Bcl-3, acting as a coactivator with NF-B p52 homodimers, was demonstrated to
directly activate the cyclin D1 promoter through an NF-B binding site. Therefore, our results demonstrate
that dysregulated expression of Bcl-3 potentiates the G1 transition of the cell cycle by stimulating the tran-
scription of the cyclin D1 gene in human breast epithelial cells.
The NF-B family of transcription factors regulates a wide
variety of cellular processes, including immune responses, cel-
lular growth and differentiation, and apoptosis (2, 11). In mam-
mals, there are five members of the NF-B family, p50, p65
(RelA), p52, c-Rel, and RelB, all of which share a conserved
Rel homology domain allowing dimerization and DNA bind-
ing. Classic NF-B, a heterodimer composed of p65 and p50
subunits, is normally found in the cytoplasm complexed with
inhibitory IB molecules. Stimulation with a variety of induc-
ers causes IB degradation, NF-B nuclear translocation and
transcriptional activation through the transactivation domain
of p65. The IB family, sharing a conserved domain of six to
seven ankyrin repeats, is composed of p105 and p100 (precur-
sors to p50 and p52, respectively), IB, IB, IBε, and Bcl-3.
Bcl-3, a candidate proto-oncogene, is upregulated transcrip-
tionally in some cases of human B-cell chronic lymphocytic
leukemia due to its location next to the breakpoint junction of
a t(14;19) translocation (20, 21, 26). Bcl-3 binds to p50 or p52
NF-B homodimers (10, 25, 38). Despite its homology to IB,
Bcl-3 can function as a coactivator when complexed with p50
or p52, which lack activation domains (4, 10). When bound to
NF-B sites as homodimers, p50 and p52 can competitively
inhibit binding of transactivating NF-B heterodimers, thus
functioning as transcriptional repressors (9). However, upon
association with Bcl-3, p50 and p52 homodimers can activate
transcription through the transactivation domain of Bcl-3 (4,
10).
Bcl-3 has properties of a transcriptional coactivator, bridging
transcription factors with the basal transcription machinery.
Bcl-3 associates with the general transcription factors TFIIB,
TATA-binding protein (TBP), and TFIIA (22). Bcl-3 also in-
teracts with other coactivators, including CBP/p300, the steroid
receptor coactivator 1 (SRC-1), and the Tip60 histone acetyl-
transferase (7, 23). In addition to p50 and p52 homodimers,
Bcl-3 has been shown to bind to the AP-1 and RXR transcrip-
tion factors, potentiating their activities (22, 23).
Recent findings correlate Bcl-3 expression with increased
cellular proliferation and survival. Thus, transgenic mice ex-
pressing Bcl-3 were found to have an expansion of B cells in
vivo, suggesting a role for Bcl-3 in B-cell proliferation (27).
Consistent with a role for Bcl-3 in proliferation, Bcl-3 is posi-
tively regulated by many growth factors (5, 29, 30, 40). Bcl-3
was also shown to cause an increased rate of DNA synthesis
when microinjected into Rat-1 cells (23). Additionally, trans-
genic mice expressing a dominant-negative NcoR corepressor
targeted to the liver showed increased levels of hepatocyte
proliferation as well as increased levels of Bcl-3 expression,
showing a correlation between Bcl-3 levels and proliferation
rates (8). However, in T cells, Bcl-3 expression does not alter
cell growth, but instead promotes cell survival. Bcl-3 expression
in interleukin 4 (IL-4)-deprived T cells protected the cells from
apoptosis (29). In T cells activated by antigenic peptides, the
addition of adjuvant increases expression of Bcl-3. Further
study showed that overexpressed Bcl-3 increased the survival
rates of the activated T cells (29). The mechanisms of Bcl-3
action in cell proliferation and cell survival have not been
described.
An important factor involved in regulating cellular prolifer-
ation is cyclin D1 (32). The association of cyclin D1 with the
cyclin-dependent kinases CDK4 and CDK6 results in phos-
phorylation of the retinoblastoma protein (Rb), thus releasing
the transcription factor E2F (3). E2F is then able to activate
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S-phase-specific genes (16). Cyclin D1 is upregulated in the
majority of human breast cancer (37). Importantly, it has been
shown that transgenic expression of cylin D1 is sufficient to
generate mammary hyperplasia and carcinoma (36), and cyclin
D1 has been shown to be required for transformation by Her-
2/Neu, a member of the epidermal growth factor (EGF) re-
ceptor family found overexpressed in a subset of breast tumors
(17). In addition, cyclin D1 is required for the malignant trans-
formation of human mammary epithelial cells by Her-2/Neu
and Ras (39). Recent data have demonstrated elevated levels
of Bcl-3, p52, and cyclin D1 in human breast cancer (6).
In this study, we investigated the effects of increased expres-
sion of Bcl-3 in immortalized human breast epithelial cells.
Our data suggest that expression of Bcl-3 leads to a shortened
G1 phase of the cell cycle and to a corresponding hyperphos-
phorylation of Rb. We also show that endogenous levels of
cyclin D1 mRNA and cyclin D1 protein are increased in these
cells as well as in cells transiently expressing Bcl-3. Further-
more, we demonstrate that Bcl-3, in cooperation with p52, can
strongly activate the cyclin D1 promoter in transient transfec-
tion assays and that a p52–Bcl-3 complex can bind to the
proximal NF-B site of the cyclin D1 promoter. Dysregulation
of Bcl-3 may promote oncogenesis through the upregulation of
cyclin D1 and the subsequent stimulation of the G1 transition.
MATERIALS AND METHODS
Cell culture and reagents. Murine NIH 3T3 fibroblasts were grown in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies,
Rockland, Md.) supplemented with 10% calf serum (HyClone Laboratories,
Logan, Utah) and penicillin-streptomycin. Immortalized human 293T kidney
cells and monkey COS-7 kidney cells were grown in DMEM supplemented with
10% fetal bovine serum (HyClone Laboratories) and penicillin-streptomycin.
H16N2 immortalized human mammary epithelial cells were grown in Ham’s F-12
medium (Life Technologies, Rockland, Md.) supplemented with hormones and
growth factors (1 g of hydrocortisone per ml, 10 ng of EGF per ml, 0 0.5 g of
Fungizone per ml, 5 mg of gentamicin per ml, 5 mM ethanolamine, 10 mM
HEPES, 5 g of transferrin per ml, 10 mM T3, 50 M selenite, 1 g of bovine
serum albumin per liter) or supplemented with hormones  10% fetal bovine
serum. Cells expressing Bcl-3 were generated by transfecting the expression
construct pFlag-Bcl-3 into H16N2 cells. Three H16N2:Bcl-3 stable clones were
generated in medium containing 1 g of puromycin per ml (Sigma, St. Louis,
Mo.). Clones were verified by Western blotting with a Bcl-3-specific antibody
(Bcl-3 C-14; Santa Cruz Biotechnology, Santa Cruz, Calif.).
Plasmid constructs. The p50, p52, and pBcl-3 expression constructs were
made by cloning PCR products in frame into the HindIII and EcoRV sites of the
pFlag-CMV2 expression vector. Plasmid integrity was verified by sequencing.
The p65 expression construct has been described previously (35). The cyclin D1
promoter reporter constructs CD1 963 WT-Luc, CD1 66 WT-Luc, and CD1
66 Mut-Luc have been previously described (1). pPCMVEGFP-spectrin (15),
pBPSTR-1 (17), and pBPSTR-1 CD1AS (17) have been described previously.
Transfection and luciferase reporter assays. Cells were transiently transfected
in six-well plates at 70% confluence with the Superfect reagent (Qiagen, Valen-
cia, Calif.) according to the manufacturer’s instructions. Briefly, plasmid con-
structs (3 g of total DNA) were diluted in serum-free medium and mixed with
the Superfect reagent. Complexes were allowed to form for 10 min before
serum-containing medium was added to the mixture. The cells were washed once
in 1 phosphate-buffered saline (PBS), and Superfect-DNA complexes were
added to the cells and placed in a humidified incubator at 37°C with 5% CO2.
Three hours posttransfection, cells were washed with 1 PBS and replenished
with fresh serum-containing medium. Forty-eight hours posttransfection, cells
were washed once in 1 PBS and lysed in Reporter lysis buffer (Promega,
Madison, Wis.) for 10 min at room temperature. Extracts were collected and
cleared by centrifugation. Protein concentration was determined with the Bio-
Rad (Hercules, Calif.) protein assay dye reagent. Luciferase assays were per-
formed with 50 g of protein per sample. D-Luciferin (Sigma, St. Louis, Mo.) was
used as a substrate, and relative light units were measured with an AutoLumat
LB953 luminometer (Berthold Analytical Instruments, Bad Wildbad, Germany).
For assays with the stable H16N2 cell lines, transfections were also done with
pCMV-LacZ to assay for transfection efficiency by counting -galactosidase-
positive cells as described previously (19).
Western analysis. Total cellular protein (50 g) was separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose membranes. Membranes were blocked and incubated for 1 h
with primary antibody. Proteins were visualized by incubation with horseradish
peroxidase-conjugated secondary antibodies and enhanced chemiluminescence
(ECL) reagents (Amersham, Piscataway, N.J.). A Bcl-3-specific antibody (Bcl-3
C-14; Santa Cruz Biotechnology), Flag-specific antibody (anti-Flag M2; Sigma),
and tubulin-specific antibody (Sigma) were used. The cyclin D1 and Rb antibod-
ies are from Pharmingen (Franklin Lakes, N.J.).
FACS analysis. H16N2:Puro or H16N2:Bcl-3 cells were grown in Ham’s F-12
medium (Life Technologies, Rockland, Md.) supplemented with hormones and
growth factors and harvested at 70% confluence. A total of 106 cells per sample
were pelleted at 500  g for 5 min and resuspended in 200 l of PBS. Cells were
fixed by adding 2 volumes of cold absolute ethanol by incubating for 1 h at 4°C.
After centrifugation at 500  g for 10 min and resuspension in PBS, RNase A,
and propidium iodide were added to final concentrations of 0.1 and 40 g/ml,
respectively. Samples were incubated at 37°C for 30 min and then stored at 4°C.
The percentage of cells in each cell cycle phase was determined by flow cytom-
etry. To show that cyclin D1 is required for the induction of the G1 phase by
Bcl-3, H16N2:Puro or H16N2:Bcl-3 cells were transfected with pBPSTR-1 or
pBPSTR-1 CD1AS plasmids along with pPCMVEGFP-spectrin at a ratio of
10:1. Forty-eight hours after transfection, cells were harvested as described above
for fluorescence-activated cell sorting (FACS). The cell cycle status of over 1,000
green fluorescent protein (GFP)-positive cells for each sample was then exam-
ined.
Cell proliferation assay. The cell proliferation enzyme-linked immunosorbent
assay (ELISA) system from Amersham Pharmacia (Peapack, N.J.) was used
according to the manufacturer’s instructions. Briefly, 5  104 cells were plated
per well of a 96-well tissue culture plate in Ham’s F-12 medium (Life Technol-
ogies) supplemented with hormones  10% fetal bovine serum. The cells were
allowed to grow for 48 h and then labeled with bromodeoxyuridine (BrdU) for
6 h. After labeling, the medium was removed, cells were fixed, and DNA was
denatured. The cells were then incubated with a blocking solution, followed by
incubation with peroxidase-labeled anti-BrdU antibody. After washing and ad-
dition of substrate, the cells were incubated for 10 min before measurement of
optical density at 450 nm.
Northern analysis. Total RNA was isolated with Trizol reagent as recom-
mended by the manufacturer (Life Technologies, Rockville, Md.). RNA samples
(10 g each) were run on an agarose gel and transferred to a nylon filter
overnight. RNA was cross-linked to the filter with a UV cross-linker (Stratagene,
La Jolla, Calif.). Filters were hybridized in QuickHyb buffer (Stratagene) in the
presence of radioactive probes following the manufacturer’s protocol. Probes
were generated from PCR fragments with a random-primed labeling kit (Life
Technologies) and with [-32P]dCTP.
EMSAs. Nuclear extracts were prepared and electrophoretic mobility shift
assays (EMSAs) were performed as previously described (18). Briefly, COS-7
cells were transfected with 1 g each of pFlag-Bcl-3, pFlag-p52, or vector control
expression constructs in various combinations. Nuclear extracts were prepared
48 h posttransfection from COS-7 cells and incubated with [-32P]dCTP-labeled,
double-stranded probes containing sequences corresponding to both wild-type
and mutant versions of the proximal NF-B site within the cyclin D1 promoter
(12). Labeled probe-nuclear extract complexes were incubated for 20 min at
room temperature and separated on a 5% polyacrylamide gel. The gel was dried
and exposed to film. For supershift analysis, p52 or Bcl-3 antibodies were incu-
bated with the nuclear extract for 10 min prior to the addition of probe. Nancy
Rice provided the human p52 antibody (no. 1267) and Timothy McKeithan
provided the Bcl-3 antibody (41) used in the supershift reactions.
RESULTS
Stable expression of Bcl-3 in breast epithelial cells leads to
enhanced progression through the G1 phase of the cell cycle.
To begin to study a potential role for Bcl-3 in oncogenesis, we
generated immortalized breast epithelial cell lines containing
either Bcl-3 (H16N2:Bcl-3) or vector control (H16N2:Puro)
plasmids (Fig. 1A). Like parental cells, H16N2:Puro cells do
not express Bcl-3, while H16N2:Bcl-3 cells express Bcl-3, as
shown by Western blot analysis (Fig. 1A). Using the H16N2:
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Bcl-3 clone 3, we then performed FACS analysis on actively
dividing cells to observe possible differences in the ability of
these cell lines to transition through the cell cycle. As shown in
Fig. 1B, a significantly lower percentage of the H16N2:Bcl-3
cell population was observed in the G1 phase of the cell cycle,
as compared to H16N2:Puro cells. Although similar percent-
ages of H16N2:Puro and H16N2:Bcl-3 cells were observed in
the S phase of the cell cycle, H16N2:Bcl-3 displayed a higher
percentage of cells in the G2/M phase of the cell cycle. There-
fore, these data suggest that the G1 phase of the cell cycle is
shortened in the H16N2:Bcl-3 cells compared to that in
H16N2:Puro cells. Other less likely alternatives are that an
increase in the growth fraction or a decrease in cell death
together with a G2/M delay could explain the results.
To show that cyclin D1 is required for the induction of the
G1 phase in H16N2:Bcl-3 cells, H16N2:Puro or H16N2:Bcl-3
cells were cotransfected with pPCMVEGFP-spectrin and ei-
ther a vector control plasmid (pBPSTR-1) or a cyclin D1 an-
tisense plasmid (pBPSTR-1 CD1AS). GFP-positive cells were
then analyzed by FACS (Fig. 1C). When transfected into
H16N:Bcl-3 cells, the cyclin D1 antisense construct caused the
percentage of cells in G1 to return to the levels seen in H16N2:
Puro cells, demonstrating a requirement for cyclin D1 in pro-
moting the G1 transition.
To determine whether the ability of Bcl-3 to potentiate tran-
sition through G1 correlates with enhanced proliferation of
the H16N2 cells, cell proliferation studies were performed by
measuring BrdU incorporation. To quantitate differences in
proliferation rates, H16N2:Puro and H16N2:Bcl-3 cells were
grown in complete media or were cultured in serum-free media
FIG. 1. Stable expression of Bcl-3 in breast epithelial cells promotes the G1 transition. (A) Creation o f stable cell lines expressing Bcl-3. H16N2
immortalized human breast epithelial cells were transfected with pFlag-CMV2 or pFlag-Bcl-3, and stable cell lines were generated (H16N2:Puro
and H16N2:Bcl-3). Western analysis with anti-Bcl-3 shows expression of Bcl-3 protein in H16N2:Bcl-3 clones 1, 2, and 3. (B) FACS analysis shows
that Bcl-3 expression leads to an accelerated G1 phase. Proliferating cells were harvested and analyzed by FACS. The percentage of cells in each
stage of the cell cycle is indicated. Data represent the mean  standard deviation of three independent experiments. (C) Cyclin D1 is required
for the induction of G1 phase in H16N2:Bcl-3 cells. Cells were cotransfected with pPCMVEGFP-spectrin and either vector control plasmid
(pBPSTR-1) or a cyclin D1 antisense plasmid (pBPSTR-1 CD1 AS). GFP-positive cells were then analyzed by FACS. In sample 1, H16N2:Puro
cells were transfected with a vector control plasmid. In sample 2, H16N2:Bcl-3 cells were transfected with a vector control plasmid. In sample 3,
H16N2:Bcl-3 cells were transfected with a cyclin D1 antisense plasmid. (D) Expression of Bcl-3 does not lead to increased cellular proliferation
in H16N2 cells. H16N2:Puro or H16N2:Bcl-3 cells were grown in the presence or absence of serum in triplicate wells of a 96-well plate. Twenty-four
hours after plating, the cells were incubated for 4 h with BrdU and analyzed by ELISA for BrdU incorporation. OD, optical density. Results
represent the mean  standard deviation of three independent experiments.
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and assayed in a cellular proliferation assay. As shown in Fig.
1D, the H16N2:Bcl-3 cells did not show a significant increase in
BrdU incorporation above levels observed for H16N2:Puro.
Our inability to detect significant differences in BrdU incorpo-
ration was also consistent with our inability to detect differ-
ences in cell growth rates (data not shown). Although Bcl-3
expression has been shown to enhance proliferation in certain
cell types (8, 23), in the immortalized breast epithelial cell line
H16N2, Bcl-3 expression alone is not sufficient to potentiate
proliferation. Additionally, the Bcl-3-expressing H16N2 cells
were not tumorigenic in nude mice (unpublished observa-
tions). These results suggest that other oncogenic events in
addition to Bcl-3 overexpression would need to take place to
facilitate dysregulated growth of breast epithelial cells.
Bcl-3 expression leads to hyperphosphorylation of Rb and
upregulation of endogenous levels of cyclin D1. Because of the
accelerated G1 transition observed in H16N2:Bcl-3 cells, we
analyzed the phosphorylation status of Rb, a key cellular reg-
ulator of the G1 transition. Once Rb becomes phosphorylated
by the cyclin D–cyclin-dependent kinase complex, it releases
the transcription factor E2F, allowing the transcription of S-
phase-specific genes and progression of the cell cycle (32).
Protein extracts isolated from H16N2:Puro and H16N2:Bcl-3
cells were resolved by SDS-PAGE, and Western blots were
probed with anti-Rb antibody. Both H16N2:Puro and H16N2:
Bcl-3 cells displayed nearly equal amounts of hypophosphory-
lated Rb (Fig. 2A, pRb and Rb bands). However, H16N2:Bcl-3
cells displayed a higher-molecular-weight hyperphosphory-
lated band, which was not observed in H16N2:Puro control
cells (Fig. 2A, ppRb band). Therefore, expression of Bcl-3 in
H16N2 cells causes increased levels of Rb phosphorylation,
consistent with our data suggesting a shortening of the G1
phase of the cell cycle.
Because the phosphorylation of Rb is regulated by the cyclin
D–cyclin-dependent kinase complex, we also analyzed the lev-
els of cyclin D present in our cell lines. RNAs were isolated,
and Northern blot analysis was performed. As shown in Fig.
2B, the levels of endogenous cyclin D1 transcripts were ele-
vated in the H16N2:Bcl-3 cells, as compared to H16N2:Puro
control cells. However, the levels of cyclin D2 and cyclin D3
mRNAs were the same in the two cell lines. Therefore, stable
expression of Bcl-3 in breast epithelial cells results in specifi-
cally higher levels of cyclin D1 RNA. A Western blot was also
performed that showed increased cyclin D1 protein expression
in the H16N2:Bcl-3 cells (Fig. 2C). For this experiment, we
analyzed all three of our H16N2:Bcl-3 clones and found that
cyclin D1 protein levels correlate with the expression level of
Bcl-3, providing further evidence that Bcl-3 regulates cyclin D1
expression.
Bcl-3 and p52 synergistically activate the cyclin D1 pro-
moter through the proximal NF-B site. Cyclin D1 has previ-
ously been shown to be regulated by classic p65-p50 NF-B
(12–14). However, in breast tumor tissues that overexpress
cyclin D1, nuclear levels of p65 are not elevated typically, while
FIG. 2. Bcl-3 expression leads to hyperphosphorylation of Rb and induction of endogenous cyclin D1 levels. (A) Fifty micrograms of total
cellular protein from the H16N2:Puro and H16N2:Bcl-3 cell lines was run on SDS-PAGE. After transfer to nitrocellulose, the membrane was
probed with an anti-Rb antibody. Of the three Rb bands detected, the upper-molecular-weight band represents hyperphosphorylated Rb (ppRB).
(B) The H16N2:Bcl-3 cell line shows increased levels of cyclin D1 RNA by Northern analysis. Cyclin D2 and cyclin D3 mRNA levels are
unchanged. Equal RNA loading was verified by using a probe for actin. (C) Cell extracts were isolated from the H16N2:Puro and H16N2:Bcl-3
cell lines and run on SDS-PAGE. After transfer to nitrocellulose, the membranes were probed with an anti-cyclin D1 antibody. Equal protein
loading was verified with antitubulin antibody.
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FIG. 3. Bcl-3 and p52 synergistically activate the cyclin D1 promoter. (A) NIH 3T3 cells were transiently cotransfected with the full-length
cyclin D1 promoter luciferase construct (CD1 963 WT-Luc) and with expression vectors encoding p50, p65, p52, and Bcl-3 proteins alone or in
combination. Forty-eight hours posttransfection, cells were harvested and luciferase assays were performed. The data presented represent the
mean  standard deviation of three independent experiments performed in triplicate. The fold inductions, as compared to the vector control, were
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nuclear levels of p50, p52, and Bcl-3 are increased (6). There-
fore, we wanted to determine if the expression of Bcl-3 could
transcriptionally regulate the cyclin D1 promoter. In order to
see if Bcl-3, complexed with p50 or p52, could activate tran-
scription of the cyclin D1 gene, NIH 3T3 cells were transiently
cotransfected with a cyclin D1 promoter luciferase construct
containing three putative NF-B sites and an AP-1 site (CD1
963 WT-Luc) and with expression vectors encoding p50, p65,
p52, and Bcl-3 proteins alone or in combination (Fig. 3A). NIH
3T3 fibroblasts were used in these studies, since these cells
normally express undetectable levels of endogenous Bcl-3 pro-
tein (unpublished observations). Although classic p65-p50
NF-B dimers activate the cyclin D1 promoter approximately
fivefold over the vector control, Bcl-3 and p52 together syner-
gistically activated the cyclin D1 promoter 24-fold over the
vector control. Interestingly, p52 and Bcl-3 activated the cyclin
D1 promoter more efficiently than p50 and Bcl-3 (Fig. 3A).
The differences in reporter activation were not due to differ-
ences in transgene expression, since similar levels of proteins
were expressed as verified by Western analysis (Fig. 3A, lower
panel).
Previously, NF-B activation of the cyclin D1 promoter has
been shown to function mainly through the proximal NF-B
site located 39 nucleotides upstream of the major start of
transcription (12–14). To determine if Bcl-3 and p52 also func-
tion through this site, NIH 3T3 cells were transiently cotrans-
fected with a cyclin D1 promoter luciferase construct contain-
ing the wild-type proximal NF-B site (CD1 66 WT-Luc) or
a mutated site (CD1 66 Mut-Luc), together with expression
vectors encoding p52 and Bcl-3 proteins (Fig. 3B). CD1 –66
does not contain the upstream AP-1 site (1). Bcl-3 and p52
were able to activate the reporter containing only the proximal
wild-type NF-B site as well as they were able to activate the
full-length reporter. Only minimal activation of the reporter
with the mutant NF-B site was observed (Fig. 3B). Therefore,
like classic NF-B, Bcl-3 also activates the cyclin D1 promoter
through the proximal NF-B site.
To confirm that Bcl-3 upregulated the cyclin D1 promoter by
directly interacting with the proximal NF-B cis element, EM-
SAs were performed (Fig. 3C). Nuclear extracts isolated from
COS-7 cells transfected with an expression plasmid encoding
p52 alone or p52 and Bcl-3 proteins together displayed DNA
binding activity that recognized the proximal NF-B element
from the cyclin D1 promoter (Fig. 3C). The observed DNA
binding activity was specific and could be supershifted with
antibodies against either Bcl-3 or p52 (Fig. 3C). Therefore,
Bcl-3 tethered to a p52 homodimer complex is specifically
targeted to the proximal NF-B cis element located in the
cyclin D1 promoter region. Bcl-3–p52 DNA complexes could
also be detected by using extracts from the H16N2:Bcl-3 cell
line (data not shown).
p52 activates the cyclin D1 promoter in a Bcl-3 stable trans-
fectant. While Bcl-3 alone is sufficient to activate the cyclin D1
gene in H16N2:Bcl-3 cells, presumably through association
with endogenous p52, we wanted to test whether expression of
p52 would increase transcription from the cyclin D1 promoter.
H16N2:Puro and H16N2:Bcl-3 cell lines were transiently trans-
fected with the cyclin D1 promoter luciferase construct (CD1
963 WT-Luc), a lacZ expression vector, and with p50, p52, or
p65 alone or in combination, as indicated (Fig. 4). Transfection
efficiency for the two cell lines was found to be equivalent, as
determined by counting -galactosidase-positive cells (data not
shown). In the H16N2:Puro cell line, addition of p50, p52, or
p65 did not significantly increase activity from the cyclin D1
reporter. However, in the H16N2:Bcl-3 cell line, p52 expres-
sion dramatically increased the activation of the cyclin D1
reporter. In contrast, overexpression of p50 or p65 did not
show a strong activation over vector control. These results
provide evidence for the cooperation of Bcl-3 and p52 in the
regulation of cyclin D1 in human breast epithelial cells.
Transient expression of Bcl-3 alone or with p52 leads to
increased levels of endogenous cyclin D1 mRNA in 293T cells.
To determine whether increased expression of Bcl-3 and p52
could lead to activation of endogenous cyclin D1 mRNA levels
in a different cell type other than breast cells, HEK 293T cells
were transfected with expression vectors encoding Bcl-3, p52,
or both, and Northern blot analysis was performed (Fig. 5).
This approach was feasible, since the transfection efficiency of
the HEK 293T cells was over 80%. Northern blots were ana-
lyzed for changes in endogenous cyclin D1 mRNA levels fol-
lowing the transient expression of Bcl-3. Bcl-3 expression alone
increased levels of cyclin D1 transcripts (Fig. 5, lane 2), as
compared to the vector control (Fig. 5, lane 1). Although p52
alone did not affect cyclin D1 expression (Fig. 5, lane 3), cells
expressing both p52 and Bcl-3 proteins displayed a significant
increase in cyclin D1 mRNA levels over that attained with
Bcl-3 alone. Equal RNA loading was verified by stripping the
blot and reprobing with an actin probe. Therefore, the regu-
lation of endogenous cyclin D1 mRNA levels by Bcl-3 is not
restricted to human breast cells.
DISCUSSION
In order to understand the potential oncogenic properties of
Bcl-3 in human breast cancer and presumably other cancers,
we have analyzed the biological consequences of Bcl-3 expres-
sion in H16N2 immortalized human breast epithelial cells. We
find that the H16N2:Bcl-3 cells have a shorter G1 phase of the
cell cycle than H16N2:Puro cells. H16N2:Bcl-3 cells also have
hyperphosphorylated Rb, which led us to test whether cyclin
D1 levels were altered. We found that endogenous levels of
plotted. (Lower panel) Western analysis showing equivalent expression of transiently transfected constructs. (B) Bcl-3 and p52 activate transcrip-
tion through the proximal NF-B site in transient transfection assays. NIH-3T3 cells were transiently cotransfected with a cyclin D1 promoter
luciferase construct containing the wild-type proximal NF-B site (CD1 66 WT-Luc) or a mutated site (CD1 66 Mut-Luc) together with
expression vectors encoding p52 and Bcl-3 proteins and assayed as described above. (C) Bcl-3 and p52 proteins bind to the proximal NF-B site
of the cyclin D1 promoter. COS-7 cells were transfected with various combinations of Bcl-3, p52, or vector control expression constructs as indicted.
Nuclear extracts were analyzed by gel shift. The identities of the bound proteins were verified by supershift (SS) with antibodies against Bcl-3 and
p52, as indicated.
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cyclin D1 mRNA and cyclin D1 protein were indeed upregu-
lated in the H16N2:Bcl-3 cells.
Most NF-B-regulated genes studied to date have been an-
alyzed in terms of their transcriptional activation by classic
p65-p50 NF-B. Little is known about the specificity of differ-
ent NF-B family members in gene regulation. Previously,
several groups have implicated NF-B p65-p50 as a positive
regulator of the cyclin D1 gene (12–14). Here we show that
Bcl-3–p52 complexes regulate the cyclin D1 promoter more
strongly than classic p65-p50 NF-B. Cyclin D1 may in fact be
a Bcl-3-responsive gene, since the expression of Bcl-3 and p52
upregulates the cyclin D1 promoter approximately fivefold
higher than classic NF-B. We further demonstrate that the
proximal NF-B site is able to bind p52–Bcl-3 complexes in
EMSAs. Bcl-3–p52 complexes have also been shown through
EMSA and reporter assays to specifically regulate the human
P-selectin promoter (28). Thus, there may be a select group of
NF-B-regulated genes that are transcriptionally controlled by
Bcl-3–p52 complexes.
Interestingly, we had found that human breast tumors con-
tain enhanced nuclear levels of p52, Bcl-3, and cyclin D1 com-
pared to normal adjacent tissue (6). Surprisingly, the same
tumors do not show elevated nuclear levels of p65. Therefore,
our finding that Bcl-3 and p52 can activate the cyclin D1
promoter may have relevance in the progression of human
breast cancer. We do note, however, that other studies have
found upregulation of the p65 subunit of NF-B in some cases
of breast cancer (24, 34). Thus, classic NF-B may also con-
tribute to cyclin D1 upregulation in certain breast cancers.
The cyclin D1 gene is overexpressed as a result of gene
amplification in many human tumors (31). However, cyclin D1
protein overexpression often occurs without a corresponding
amplification of the cyclin D1 locus. In breast cancer, for ex-
ample, the frequency of cyclin D1 gene amplification is low,
while most breast cancers overexpress the cyclin D1 protein
(31). Therefore, dysregulation of the regulatory pathways that
control cyclin D1 expression is likely to play a role in breast
cancer. Cyclin D1 has been shown to contribute directly to
breast oncogenesis in transgenic mice. For example, a targeted
overexpression of cyclin D1 in murine mammary epithelial
cells results in ductal hyperproliferation and tumor formation
(36). Mice null for cyclin D1, on the other hand, exhibit defects
in mammary lobuloalveolar development during pregnancy
(33). Furthermore, cyclin D1 has been shown to be required
for transformation induced by Her-2/Neu (17). Therefore, the
critical role that cyclin D1 plays in normal breast development
may be coupled to its tumorigenic properties when aberrantly
expressed.
In most systems studied so far, Bcl-3 has been found to be a
proliferative factor (8, 23). This is logical, since Bcl-3 is in-
duced by a variety of growth-promoting cytokines in multiple
cell types (5, 29, 30, 40). We have shown that this is also true
in breast cells. In MCF7 breast carcinoma cells, Bcl-3 mRNA
is induced by tumor necrosis factor alpha (TNF-), IL-1, and
platelet-derived growth factor (PDGF-) (unpublished obser-
vations). In the H16N2 normal breast epithelial cell line ex-
pressing Bcl-3, however, we did not observe a significant in-
crease in cell proliferation, even though the level of cyclin D1
mRNA is increased. However, we demonstrate an increase in
hyperphosphorylated Rb, the biological target of cyclin D1 and
associated kinases. This correlates with a potentially shorter G1
phase of the cell cycle, as measured by FACS. However, the
overall cell cycle time is not changed in the H16N2:Bcl-3 cells,
because the cells do not grow significantly faster than the
H16N2:Puro cells (data not shown). Our FACS data suggest
that the G2/M phase of the cell cycle is lengthened, thus mak-
ing up for the shortened G1 phase and allowing total cell
division time to remain the same. At present, we do not know
the reason for the lengthened G2/M phase. In our system, we
hypothesize that other genes may be required to act in concert
with Bcl-3 to increase the overall rate of cellular proliferation
and/or oncogenic potential.
Taken together, our data establish a link between upregu-
lated nuclear levels of Bcl-3 and p52 in breast cancer cells with
upregulated levels of cyclin D1. We show that cyclin D1 is
transcriptionally activated by Bcl-3–p52 complexes more effi-
FIG. 4. Activation of the cyclin D1 promoter by p52 in Bcl-3 stable
breast epithelial cells. H16N2:Puro and H16N2:Bcl-3 cell lines were
transiently transfected with the cyclin D1 promoter luciferase con-
struct (CD1 963 WT-Luc), a lacZ expression vector, and with ex-
pression vectors encoding p50, p52, and p65 proteins alone or in
combination. Forty-eight hours posttransfection, cells were harvested
and luciferase assays were performed. Transfection efficiency for the
two cell lines was found to be equivalent, as determined by counting
-galactosidase-positive cells (data not shown). The data presented
represent the mean  standard deviation of luciferase expressions of
three independent experiments performed in triplicate. The fold in-
ductions, as compared to that of the vector control, were plotted.
FIG. 5. Bcl-3 and p52 proteins upregulate endogenous cyclin D1
mRNA in 293T cells. 293T cells were transfected with various combi-
nations of Bcl-3, p52, or vector control expression constructs as indi-
cated. RNA was isolated, and Northern blot analysis was used to probe
for levels of cyclin D1 mRNA. An actin probe was used to verify equal
RNA loading.
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ciently than by p65-p50 complexes. The increased levels of
cyclin D1 in the Bcl-3-expressing cells led to hyperphosphory-
lated Rb and a shortened G1 transition, but not to significantly
increased levels of cellular proliferation. We note that the
H16N2:Bcl-3 cells do not form tumors in nude mice (unpub-
lished observations). Because cancer is a multistep process, we
propose that Bcl-3 may promote increased cell growth in com-
bination with other oncogenes. Bcl-3 has been shown by
EMSA and reporter assays to specifically regulate the human
P-selectin promoter (28). To our knowledge, cyclin D1 is the
first endogenous gene shown to be regulated by Bcl-3. In ad-
dition to cyclin D1, it will also be important to study other
proto-oncogenes that may be overexpressed by aberrant ac-
tivation of Bcl-3 or that may cooperate with Bcl-3 to pro-
mote oncogenesis.
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